Profile data is unavailable for this security.
About the company
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. It is in the process of building its preclinical pipeline, which focuses primarily on immuno-oncology. Its pipeline includes IBIO-101, Endostatin E4, TROP-2 x CD3, MUC16, EGFRvIII, and CCR8. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.
- Revenue in USD (TTM)50.00k
- Net income in USD-17.13m
- Incorporated2008
- Employees26.00
- LocationIbio Inc8800 HSC PkwyBRYAN 77807United StatesUSA
- Phone+1 (979) 446-0027
- Fax+1 (302) 636-5454
- Websitehttps://www.ibioinc.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eiger Biopharmaceuticals Inc | 15.77m | -74.96m | 17.10m | 25.00 | -- | -- | -- | 1.08 | -50.80 | -50.80 | 10.69 | -9.77 | 0.1985 | 0.0064 | 9.19 | 630,920.00 | -94.31 | -60.25 | -186.10 | -76.51 | 99.91 | -- | -475.26 | -823.59 | 0.6809 | -22.03 | 1.54 | -- | 16.98 | -- | 22.54 | -- | 10.51 | -- |
GlycoMimetics Inc | 10.00k | -37.28m | 17.19m | 35.00 | -- | 0.5943 | -- | 1,718.62 | -0.5791 | -0.5791 | 0.0002 | 0.4486 | 0.0002 | -- | 0.0581 | 285.71 | -72.29 | -43.60 | -81.84 | -47.82 | -- | -- | -372,767.40 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
Vincerx Pharma Inc | 0.00 | -38.25m | 17.48m | 42.00 | -- | -- | -- | -- | -1.79 | -1.79 | 0.00 | -0.029 | 0.00 | -- | -- | 0.00 | -130.68 | -- | -205.70 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 36.24 | -- | -- | -- |
Pharmacyte Biotech Inc | 0.00 | -14.82m | 17.58m | 2.00 | -- | 0.5649 | -- | -- | -1.64 | -1.64 | 0.00 | 5.74 | 0.00 | -- | -- | 0.00 | -1.53 | -13.35 | -1.62 | -13.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1.81 | -- | -- | -- |
Nuo Therapeutics Inc | 782.01k | -3.02m | 17.59m | -- | -- | 51.74 | -- | 22.50 | -0.071 | -0.071 | 0.0183 | 0.0075 | 0.4516 | 0.7856 | 4.30 | -- | -174.64 | -116.16 | -294.62 | -354.84 | 78.74 | 70.02 | -386.76 | -854.53 | 1.01 | -1,418.93 | 0.00 | -- | 442.12 | -14.99 | 0.0095 | -- | -- | -- |
Aytu Biopharma Inc | 93.76m | -13.68m | 17.62m | 150.00 | -- | 0.5337 | -- | 0.1879 | -2.65 | -2.65 | 18.21 | 5.53 | 0.6792 | 2.42 | 2.93 | 625,053.30 | -9.91 | -33.56 | -25.58 | -52.81 | 65.32 | 56.89 | -14.60 | -73.81 | 0.6923 | 0.216 | 0.352 | -- | 11.10 | 96.56 | 84.33 | -- | -- | -- |
VBI Vaccines Inc | 9.41m | -83.99m | 17.74m | 131.00 | -- | -- | -- | 1.89 | -6.93 | -6.93 | 0.4818 | -0.2166 | 0.0923 | 1.40 | 37.05 | 71,839.70 | -81.40 | -46.58 | -171.57 | -58.62 | -24.06 | -277.46 | -881.79 | -2,755.98 | 0.2116 | -1.60 | 1.13 | -- | 702.40 | 20.94 | 17.18 | -- | -32.07 | -- |
Synlogic Inc | 3.21m | -73.22m | 17.79m | 6.00 | -- | 1.33 | -- | 5.55 | -10.62 | -10.62 | 0.4576 | 1.15 | 0.0495 | -- | -- | 534,166.70 | -113.09 | -40.57 | -134.57 | -43.82 | -- | -- | -2,284.68 | -3,245.93 | -- | -- | 0.00008 | -- | 185.68 | 5.99 | 13.40 | -- | -48.05 | -- |
Mustang Bio Inc | 0.00 | -40.10m | 17.83m | 80.00 | -- | -- | -- | -- | -4.55 | -4.55 | 0.00 | -0.4757 | 0.00 | -- | -- | 0.00 | -90.93 | -70.02 | -138.05 | -79.98 | -- | -- | -- | -- | -- | -15.88 | -- | -- | -- | -- | 33.44 | -- | -60.75 | -- |
Forte Biosciences Inc | 0.00 | -32.14m | 17.86m | 11.00 | -- | 0.6217 | -- | -- | -1.03 | -1.03 | 0.00 | 0.7882 | 0.00 | -- | -- | 0.00 | -93.54 | -72.06 | -104.30 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
Ibio Inc | 50.00k | -17.13m | 18.02m | 26.00 | -- | 0.716 | -- | 360.47 | -13.10 | -17.09 | 0.0262 | 2.92 | 0.0011 | -- | 0.0065 | 1,923.08 | -36.24 | -28.09 | -67.39 | -32.63 | -- | -- | -34,258.00 | -1,467.30 | -- | -- | 0.3666 | -- | -100.00 | -- | 0.9764 | -- | 42.90 | -- |
Lumos Pharma Inc | 1.53m | -37.13m | 18.42m | 33.00 | -- | 1.06 | -- | 12.08 | -4.59 | -4.59 | 0.1886 | 2.15 | 0.0332 | -- | 8.01 | 46,212.12 | -80.89 | -29.78 | -90.15 | -32.32 | -- | -- | -2,434.69 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
MEI Pharma Inc | 66.75m | 26.16m | 18.52m | 46.00 | 0.7082 | 0.363 | 0.6987 | 0.2775 | 3.93 | 3.93 | 10.02 | 7.66 | 0.6498 | -- | 29.15 | 1,451,174.00 | 25.46 | -25.31 | 30.38 | -28.59 | -- | -- | 39.18 | -122.05 | -- | -- | 0.00 | -- | 19.95 | 97.56 | 41.53 | -- | -- | -- |
Cara Therapeutics Inc | 16.94m | -122.54m | 18.58m | 55.00 | -- | 0.6235 | -- | 1.10 | -2.26 | -2.26 | 0.3118 | 0.5452 | 0.1392 | 1.34 | 4.35 | 307,963.60 | -100.70 | -35.76 | -115.83 | -40.82 | 75.18 | -- | -723.49 | -162.10 | 5.20 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
Nymox Pharmaceutical Corp | 0.00 | -4.87m | 18.89m | 3.00 | -- | -- | -- | -- | -0.0536 | -0.0536 | 0.00 | -0.0204 | 0.00 | -- | -- | -- | -255.75 | -264.40 | -- | -464.48 | -- | -- | -- | -13,001.67 | -- | -42.44 | -- | -- | -- | -- | 47.55 | -- | -- | -- |
Indaptus Therapeutics Inc | 0.00 | -14.98m | 18.96m | 7.00 | -- | 2.03 | -- | -- | -1.78 | -1.78 | 0.00 | 1.10 | 0.00 | -- | -- | 0.00 | -87.86 | -66.55 | -97.46 | -81.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.68 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Adar1 Capital Management LLCas of 05 Apr 2024 | 789.29k | 9.15% |
Opaleye Management, Inc.as of 01 Apr 2024 | 650.00k | 7.54% |
Lynx1 Capital Management LPas of 31 Mar 2024 | 600.00k | 6.96% |
Ikarian Capital LLCas of 31 Mar 2024 | 600.00k | 6.96% |
Armistice Capital LLCas of 31 Mar 2024 | 350.88k | 4.07% |
Renaissance Technologies LLCas of 31 Mar 2024 | 15.88k | 0.18% |
Sabby Management LLCas of 31 Mar 2024 | 14.00k | 0.16% |
FNY Capital Management LPas of 31 Mar 2024 | 9.00k | 0.10% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 5.82k | 0.07% |
Tower Research Capital LLCas of 31 Mar 2024 | 5.60k | 0.07% |